Retroperitoneal and mesenteric liposarcomas.
Abstract
Retroperitoneal liposarcomas are a rare entity and are comprised mostly of the well-differentiated and dedifferentiated subtypes. Eight-year survival ranges from 30% to 80% depending on histologic subtype and grade. Surgery is the cornerstone of treatment and compartment resection is the current standard. Mesenteric liposarcomas are extremely rare and comprise more high-grade lesions, with poorer prognosis of 50% 5-year overall survival. They are managed with a similar aggressive surgical approach. This review presents the current management of retroperitoneal and mesenteric liposarcomas.
Author
Siew, Caroline C H
Apte, Sameer S
Baia, Marco
Gyorki, David E
Ford, Samuel
van Houdt, Winan J
Apte, Sameer S
Baia, Marco
Gyorki, David E
Ford, Samuel
van Houdt, Winan J
Citations
Altmetric:
Date
2022-07
Type
Article
Subject
Surgery
Collections
Citation
Siew CCH, Apte SS, Baia M, Gyorki DE, Ford S, van Houdt WJ. Retroperitoneal and Mesenteric Liposarcomas. Surg Oncol Clin N Am. 2022 Jul;31(3):399-417. doi: 10.1016/j.soc.2022.03.005
Journal / Source Title
Surgical Oncology Clinics of North America
DOI
10.1016/j.soc.2022.03.005
PMID
35715141
Publisher
Elsevier
Publisher’s URL
http://www.sciencedirect.com/science/journal/10553207